AstraZeneca-Daiichi
breast cancer treatment scored promising results
The breast cancer drug trastuzumab deruxtecan developed by AstraZeneca and Daiichi Sankyo showed positive results in a metastatic breast cancer trial. AstraZeneca remunerated Daiichi Sankyo USD 1.35 billion upfront and guaranteed up to USD 6.9 billion overall to secure rights. The British company gave USD 3.5 billion to fund the agreement.
Novartis remunerates
USD 5.3 billion to Takeda for eye drug
Takeda Pharmaceutical nods to sell its dry eye drug to Novartis for USD 3.4 billion and milestone payments up to USD 1.9 billion. The Japanese group had arrived an agreement to sell its Xiidra pr...
